A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome-Reference-Cited by-同舟云学术

A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome

Published:2021-06-20 Issue:3 Volume:54 Page:281-291
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Nulsen Benjamin¹^ORCID,LeBrett Wendi¹,Drossman Douglas A.²,Chang Lin¹

Affiliation:

1. Department of Medicine and Vatche and Tamar Manoukian Division of Digestive Diseases David Geffen School of Medicine University of California Los Angeles CA USA

2. Center for Education and Practice of Biopsychosocial Care Drossman Gastroenterology University of North Carolina Chapel Hill NC USA

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16467

Reference42 articles.

1. Bowel Disorders

2. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV

3. Irritable Bowel Syndrome

4. Irritable bowel syndrome: A clinical review

5. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut−Brain Interaction): A Rome Foundation Working Team Report

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosing and managing irritable bowel syndrome with predominant diarrhoea in clinical practice: online survey among gastroenterologists and general practitioners;Acta Gastro Enterologica Belgica;2024-06

2. Treating disorders of brain–gut interaction with multidisciplinary integrated care. Moving towards a new standard of care;JGH Open;2024-05

3. Central Neuromodulators in Irritable Bowel Syndrome: Why, How, and When;American Journal of Gastroenterology;2024-04-09

4. Diagnosing and managing irritable bowel syndrome with predominant diarrhoea in clinical practice: online survey among gastroenterologists and general practi-tioners;ACTA GASTRO-ENT BELG;2024

5. Most patients with disorders of gut‐brain interaction receive pharmacotherapy with major or moderate drug‐gene interactions;Neurogastroenterology & Motility;2023-12-10